GSK says blood cancer drug shows dramatic survival gains in key trial
GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep (belantamab mafodotin) significantly extended survival in a pivotal trial. The drug, combined with two other therapies, reduced the risk of death by 42% compared to a rival treatment from Johnson & Johnson (NYSE:JNJ), according to results presented at the American Society of Hematology's annual meeting.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
GSK Expands Vaccine Collaboration With Zhifei in China
GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.
GSK extends vaccine partnership with Zhifei in China
GSK PLC (LSE:GSK, NYSE:GSK) has extended its partnership with Chongqing Zhifei Biological Products (Zhifei) to bring its shingles vaccine, Shingrix, to mainland China through 2034. The revised agreement builds on a previous three-year deal and includes exclusive rights for Zhifei to import, distribute, and promote Shingrix.
GSK, China's Zhifei Expand Shingles Shot Collaboration
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration
GSK said on Thursday it has expanded its agreement with China's Zhifei to explore a collaboration with the Chinese vaccines company on the British drugmaker's respiratory syncytial virus (RSV) vaccine, Arexvy.
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo
The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease.
GSK's receives European Commission green light for liquid form of key vaccine
GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine, which protects against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y. This updated formulation eliminates the need for reconstitution before use, simplifying the vaccination process for healthcare providers.
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GSK submits multiple myeloma treatment for approval to the US regulator
The US Food and Drug Administration (FDA) has accepted GSK PLC (LSE:GSK, NYSE:GSK)'s application to review the use of Blenrep (belantamab mafodotin) in treating relapsed or refractory multiple myeloma, a blood cancer. If approved, Blenrep could be combined with bortezomib and dexamethasone (BorDex) or pomalidomide and dexamethasone (PomDex) for patients who have already undergone at least one prior therapy.
GSK's RSV vaccine gets greenlight in Japan
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan's Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related outcomes. The vaccine was previously approved in Japan for individuals aged 60 and older.
